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As an essential component of innate immunity, macrophages have multiple functions in
both inhibiting or promoting cell proliferation and tissue repair. Diversity and plasticity are
hallmarks of macrophages. Classical M1 and alternative M2 activation of macrophages,
mirroring the Th1–Th2 polarization of T cells, represent two extremes of a dynamic chang-
ing state of macrophage activation. M1-type macrophages release cytokines that inhibit the
proliferation of surrounding cells and damage contiguous tissue, and M2-type macrophages
release cytokines that promote the proliferation of contiguous cells and tissue repair. M1–
M2 polarization of macrophage is a tightly controlled process entailing a set of signaling
pathways, transcriptional and posttranscriptional regulatory networks. An imbalance of
macrophage M1–M2 polarization is often associated with various diseases or inflammatory
conditions.Therefore, identification of the molecules associated with the dynamic changes
of macrophage polarization and understanding their interactions is crucial for elucidating
the molecular basis of disease progression and designing novel macrophage-mediated
therapeutic strategies.
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INTRODUCTION
As an essential component of innate immunity, macrophages are
capable of differentiating into protean varieties with a range of
function (1–3). In respond to various environmental cues (e.g.,
microbial products, damaged cells, activated lymphocytes) or
under different pathophysiologic conditions, macrophages can
acquire distinct functional phenotypes via undergoing differ-
ent phenotypic polarization (4). Macrophage M1 and M2-type
responses describe the opposing activities of killing or repair-
ing, and such polarized responses stimulate Th1- or Th2-like
responses in macrophages, respectively. First, M1 phenotype is
stimulated by microbial products or pro-inflammatory cytokines
[IFN-γ, TNF, or Toll-like receptor (TLR) ligands], and the typi-
cal characteristics of M1 macrophages include high antigen pre-
sentation, high production of IL-12 and IL-23, and high pro-
duction of nitric oxide (NO) and reactive oxygen intermediates
(ROI) (5). In contrast, M2-type responses are the “resting” phe-
notype and are observed in healing-type circumstances without
infections. Such responses can also be further amplified by IL-
4, IL-10, or IL-13. M2 macrophages are characterized by the
upregulation of Dectin-1, DC-SIGN, mannose receptor, scavenger
receptor A, scavenger receptor B-1, CD163, CCR2, CXCR1, and
CXCR2 (6). Instead of generating NO or ROI, M2 macrophages
produce ornithine and polyamines through the arginase path-
way (2, 7). In fact, from the functional point view, NO and
Ornithine, correlating to killing (M1) and repairing function (M2)
of macrophages, have been regarded by some investigators as the
most characteristic molecules of macrophages (8). Second, inflam-
matory M1 macrophages produce many other pro-inflammatory
cytokines like TNFα, IL-1, IL-6, IL-12, Type I IFN, CXCL1-3,
CXCL-5, and CXCL8-10 (9), while M2 macrophages generate anti-
inflammatory cytokine such as IL-10 and very low level of pro-
inflammatory cytokine such as IL-12 (10). Additional signatures
of M2 phenotype, such as YM1 (a member of the chitinase fam-
ily) and FIZZ1 (found in inflammatory zone 1, RETNLA) are also
identified (11). Third, M1 macrophages promote Th1 response
and possess strong microbicidal and tumoricidal activity, while
M2 macrophages are involved in metazoan parasites containment
and promotion of Th2 response, tissue remodeling, immune tol-
erance, and tumor progression (12, 13). Additional information
about polarized activation of macrophages can be found in the
previous reviews (1, 14–16).
A coordinate action of various inflammatory modulators, sig-
naling molecules, and transcription factors is involved in regu-
lating macrophage polarization. At cellular level, although M1
and M2 macrophage activities exist without T or B cell influence
(17), specialized or polarized T cells (Th1, Th2, Tregs) do play a
role in macrophage polarized activation (1). Canonical IRF/STAT
signaling is a central pathway in modulating macrophage polar-
ization. Activation of IRF/STAT signaling pathways by IFNs and
TLR signaling will skew macrophage function toward the M1 phe-
notype (via STAT1), while activation of IRF/STAT (via STAT6)
signaling pathways by IL-4 and IL-13 will skew macrophage func-
tion toward the M2 phenotype (9). Signals initiated by IL-10,
glucocorticoid hormones, apoptotic cell-released molecules, and
immune complexes can also profoundly affect macrophage func-
tional statue (1). Macrophage polarization is also modulated
by local microenvironmental conditions such as hypoxia (18).
More importantly, M1–M2 polarization of macrophage is a highly
dynamic process and the phenotype of polarized macrophages
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can be reversed under physiological and pathological conditions
(19, 20). In the course of various pathophysiological settings, the
same signaling pathway can be involved in either M1 or M2 polar-
ization of macrophages. The molecular mechanisms that govern
the phenotype switch of macrophages, however, remains incom-
pletely understood. Moreover, imbalances of macrophage M1–M2
polarization are associated with various diseases. Disease condi-
tions are frequently associated with polarization of macrophage
activation, with classically activated M1 macrophages implicated
in initiating and sustaining inflammation and M2 macrophages
associated with resolution of chronic inflammation (6). In the
past decade, a new class of small non-coding RNAs, termed as
microRNAs (miRNAs), have emerged as important regulators in
biological processes. An important role of miRNAs in modu-
lating macrophage phenotypic polarization is demonstrated by
accumulating evidences in which an excessive or impaired inflam-
matory response of macrophages is found to be tightly linked to
the deregulation of miRNAs. In this review, we focus on recent
progress in understanding the molecular basis underlying the
dynamic macrophage polarization, including signaling pathways,
transcription factors and miRNAs.
IRF/STAT SIGNALING
As shown in Figure 1, IRF/STAT signaling is a central pathway
in controlling macrophage M1–M2 polarization. Toll-like recep-
tor signaling, particularly TLR4 stimulated by lipopolysaccharide
(LPS) and other microbial ligands, drives macrophages to a prefer-
entially M1 phenotype. Two adaptors, MyD88 and TRIF, mediate
the signaling downstream of TLR4. The signaling pathway through
the MyD88 adaptor results in the activation of a cascade of kinases,
including IRAK4, TRAF6, and IKKβ, which finally leads to the acti-
vation of nuclear factor kappa B (NF-κB). As a key transcription
factor related to macrophage M1 activation, NF-κB regulates the
expression of a large number of inflammatory genes including
TNFα, IL1B, cyclooxygenase 2 (COX2), IL-6, and IL12p40. NF-κB
activity is modulated via the activation of the inhibitor of kappa
B kinase (IKK) trimeric complex (two kinases, IKKα, IKKβ, and a
regulatory protein, IKKγ). When upstream signals converge at the
FIGURE 1 | Mechanisms underlying the polarization of
macrophages. The major regulatory pathways of macrophage M1–M2
polarization are outlined. The crosstalk between the M1 and M2
macrophage polarizing pathways, particularly the balance between
activation of STAT1 and STAT3/STAT6, tightly regulates macrophage
polarization and activity. A predominance of NF-κB and STAT1 activation
promotes M1 macrophage polarization, resulting in cytotoxic and
tissue-damage proinflammatory functions. In contrast, a predominance
of STAT3 and STAT6 activation by IL-4/13 and IL-10 increases M2
macrophage polarization, associated with immune tolerance and tissue
repairing. PPARδ (and PPARγ) control distinct aspects of M2 macrophage
activation and oxidative metabolism. KLF-4, a downstream of STAT6,
participates in the promotion of M2 macrophage functions by
suppressing the NF-κB/HIF-1α-dependent transcription. IL-4 induces not
only c-Myc, which controls the expression of a subset of M2-associated
genes but also the M2-polarizing IRF-4 axis to inhibit IRF5-mediated M1
polarization. IL-10 promotes M2 polarization through the induction of p50
NF-κB homodimer, c-Maf, and STAT3 activities. MicroRNAs such as
miR-155, miR-223, etc. are involved in modulating macrophage
polarization via targeting SOCS1, CEBP, and Pknox1, respectively.
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IKK complex, they first activate IKKβ via phosphorylation, and
activated IKKβ further phosphorylates the inhibitory molecule,
inhibitor of kappa B (I-κB). This results in the proteosomal degra-
dation of I-κB and the release of NF-κB p65/p50 heterodimer from
the NF-κB/I-κB complex. The NF-κB p65/p50 heterodimer is then
translocated to the nucleus and binds to the promoters of inflam-
matory genes. The signaling through the TRIF adaptor pathway
activates the transcription factor interferon-responsive factor 3
(IRF3), leading to the expression and secretion of type I inter-
feron, such as IFNα and IFNβ. Secreted type 1 interferons bind to
the type I interferon receptor (IFNAR) with consequent activation
of the transcription factor STAT1. It has been widely reported that
IRF3 and IRF5 are involved in regulating M1 polarization and M1-
associated gene induction (21, 22). IFN-stimulated genes include
chemokine CXCL9 and CXCL10 (23), which are characteristic of
classical M1 macrophage activation. In fact, macrophage polar-
ization is tightly linked to the differential expression of various
TLRs on macrophages. The ratio of TLR4/TLR2 is significantly
higher in M1 macrophages compared to M2 macrophages (24),
while TLR4 deficiency promotes the alternative activation (M2)
of adipose tissue macrophages (ATMs) (25). TLR ligands, e.g.,
imiquimod and CpG, have been used as therapeutic treatments for
inflammatory diseases such as asthma by modulating macrophage
polarization.
Toll-like receptor and Toll-like receptor-induced cytokine-
receptor cascades are broadly inhibited by tyrosine kinases Tyro3,
Axl, and Mer. IFNβ can activate the receptor for Axl, Tyro3, and
Mer and negatively regulate TLR signaling through induction of
SOCS1 and SOCS3 (26). A hyperactive signaling mediated by
Tyro3, Axl, and Mer receptor is suggested to induce immuno-
suppression in severe sepsis patients (26). Along the same lines,
chronic signaling through the TLR4 pathway has been shown
to induce various negative regulators like IRAK-M, ST2, SOCS1,
short version of MyD88 (MyD88sh) (27, 28) and SHIPs (29).
These negative regulators inhibit TLR-mediated signaling and
thus switch macrophages to an immunosuppressive, endotoxin-
tolerant phenotype. A switching from an MyD88-dependent to
a TRIF-dependent TLR4 pathway in macrophages has also been
suggested to shift macrophage phenotype from an inflammatory
to anti-inflammatory, endotoxin-tolerant phenotype (30). Thus,
interplay of signaling molecules and transcription factors can
reverse the phenotype of macrophage polarization.
STAT-mediated activation of macrophages is regulated by
members of the suppressor of cytokine signaling (SOCS) family.
SOCS family members are inducible inhibitors of cytokine signals
and thus play a critical role in limiting inflammation responses.
SOCS proteins could be induced by cytokine signaling pathway,
and they in turn inhibit the cytokine signaling by several mech-
anisms. For example, IL-4 and IFN-γ, the latter in concert with
TLR stimulation, upregulate SOCS1 (31) and SOCS3 (32), which
in turn, inhibit the action of STAT1 and STAT3, respectively.
SOCS proteins can be also directly induced by TLR signaling.
In macrophages, SOCS proteins not only regulate the sensitiv-
ity of cells toward cytokines but also modulate signaling through
TLRs. Because SOCS3 is a downstream molecule of Notch signal-
ing (33), it is likely that Notch signaling determines the M1 versus
M2 polarization of macrophages through SOCS3 (34). However,
the role of SOCS3 in modulating macrophage M1–M2 polariza-
tion is controversial. Although the unique expression of SOCS3
was reported to be essential for classic macrophage activation (32),
SOCS3 deficiency also promotes M1 macrophage polarization and
inflammation (35).
Macrophages can be driven to M2 phenotype by canoni-
cal M2 stimuli like IL-4, IL-13, and IL-10 (36, 37). As shown
in Figure 1, IL-4 and IL-13 polarize macrophages to M2 phe-
notype via activating STAT6 through the IL-4 receptor alpha
(IL-4Rα), whereas IL-10 promotes M2 phenotype via activating
STAT3 through receptor (IL-10R). In IL-4 and IL-13 pathway,
receptor binding of IL-4 activates JAK1 and JAK3 (38), leading
to STAT6 activation and translocation. Macrophage M2 phe-
notype is promoted by several transcription factors, including
peroxisome proliferator activated receptor γ (PPARγ) (39, 40)
and Krueppel-like factor 4 (KLF-4) (41). Myeloid-specific defi-
ciency of either PPARγ or KLF-4 resulted in suppressed M2
polarization of macrophages, leading to accelerated lesion forma-
tion in apolipoprotein E-deficient (42) or low-density lipoprotein
receptor-knockout (43) mice. Moreover, ligation of PPARγ by spe-
cific PPARγ ligands resulted in a preferential M2 polarization
in mice and in human beings (40). Other transcription factors
involved in this process include c-Myc and IRF4. Transciptome
analysis of IL-4-stimulated cells consists of various enzymes and
transcription factors, including transglutaminase 2 (TGM2), man-
nose receptor, cholesterol hydroxylase CH25H, prostaglandin-
endoperoxide synthase PTGS1 (prostaglandin G/H synthase 1),
transcription factors IRF4, KLF-4, and the signaling modulators
CISH and SOCS1 (44). During severe respiratory syncytial virus
(RSV)-induced bronchiolitis, IL-4Rα/STAT6-dependent M2 dif-
ferentiation of macrophages reduces inflammation and epithelial
damage in lungs (45).
PPARγ play an important role in modulating macrophage
M2 polarization induced by IL-4 or IL-13 (46). Studies using
PPARγ-deficient macrophages have shown the role of this nuclear
receptor in promoting M2 activation to protect mice from insulin
resistance (47). A similar role was also found for the PPARδ in
determination of macrophage polarization (48). Using myeloid-
specific transcription factor KLF-4 knockout mice, Liao et al.
(41) demonstrated the role of KLF-4 in regulating M2 polariza-
tion of macrophages as well as in protecting mice from obesity-
induced insulin resistance. In a similar fashion, IRF4 is also
involved in regulating the expression of genes associated with
macrophage M2 polarization (49). Collectively, all these findings
suggest that STAT6, PPARγ, KLF-4, and IRF4 may coordinate the
M2 polarization of macrophages.
IL-10R, a heterodimer of IL-10R1 and IL-10R2, is a receptor for
IL-10. Ligation of IL-10R with IL-10 results in the autophospho-
rylation of IL-10R, leading to the activation of the transcription
factor STAT3 and reduction of pro-inflammatory cytokine expres-
sion. In macrophages, IL-10 is also reported to respond to TLR
activation, glucocorticoid treatment, and C-type lectin signaling
(e.g., DC-SIGN and dectin 1 ligation). The components in IL-
10-induced macrophage transcriptome include specific Fc recep-
tors, chemoattractants CXCL13 and CXCL4, recognition receptors
formyl peptide receptor 1 (FPR1), TLR1, TLR8, and macrophage
receptor with collagenous domain (50).
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HIF-1α AND HIF-2α
Macrophages can rapidly alter their metabolic and functional
state to adapt to the microenvironment of surrounding tissues.
Microenvironmental conditions in infected, inflamed, or dam-
aged tissues are generally lack of oxygen and nutrients. When
macrophages are recruited into inflammatory sites, they encounter
the hypoxia condition, which can directly affect the macrophage
polarization. Hypoxia executes its effect on macrophages through
two isoforms of hypoxia-inducible factor (HIF), HIF-1α and HIF2
(51, 52). Gene expression profiling of macrophages and mono-
cytes has identified profound changes in response to hypoxia (53,
54). Hypoxia strongly induces the expression of angiogenesis-
and metastasis-related genes such as VEGF, FGF2, MMP7, and
MMP9. Upregulation of those genes under hypoxia would lead
to more recruitment of macrophages into the hypoxic (avascu-
lar) areas in pathologies like atherosclerosis, obesity, and cancer
where they dampen the inflammation or promote tumor progres-
sion. In addition, pro-inflammatory cytokines like TNFα, IL-1β,
MIF, CCL3, and COX2, as well as M2 markers like IL-10 and
arginase 1 in macrophages, are also induced by hypoxia (55).
The crucial role of hypoxia in regulating macrophage inflam-
matory response has been confirmed in mice with myeloid cell-
specific deletion of HIF-1α (56), in which HIF-1α was found to
be essential in regulating myeloid cell glycolytic capacity and sur-
vival and function in the inflammatory microenvironment. This
is in line with the finding that HIF-1α was induced by NF-κB
(57) and plays an important role in modulating macrophage
phagocytosis of bacteria under sepsis conditions (58). More-
over, recent studies also showed that HIF-1α can mediate the
effects of tumor-derived lactic acid (59) and cytokines (Onco-
statin M and Eotaxin) (60) on promoting M2-like phenotype. In
contrast to these studies, recent study of myeloid-specific HIF-
2α deletion showed the role of HIF2 in mediating macrophage
inflammatory responses rather than HIF-1α (52). In contrast to
these studies, a recent (61) suggested that HIF-1α and HIF-2α
might also drive macrophage polarization by modulating NO
homeostasis in a cytokine-induced and transcription-dependent
fashion. Specifically, this study showed that inducible NO syn-
thase gene and the arginase 1 gene in polarized macrophages are
specifically regulated by HIFs (61). Although HIF-1α and HIF-2α
displayed physiologically antagonistic functions, their antiphase
regulation allows them to coordinately regulate NO production
to guide macrophage polarization. Together, these findings sug-
gest HIFs as an important regulator of macrophage polarization,
although a detailed dissection of whether the alteration of HIF iso-
form expression can switch macrophage phenotypes needs further
investigation.
OLIGOMERIZATION DOMAIN (NOD)-LIKE RECEPTORS
Stimulated by a diverse set of stimulus, including interferon-γ
(IFN-γ), LPS, and other TLR activators, macrophages are polar-
ized toward to M1 state in which oxidative metabolites and pro-
inflammatory cytokines are produced. Engagement of the respec-
tive receptors by these stimulus results in activation of the adapter
proteins such as MyD88, leading to sequential activation of kinases,
phosphorylation of transcription factors, and eventual genetic
program induction. Pro-inflammatory genes, including IFN-γ,
tumor necrosis factor-α (TNF-α), IL-1β, IL-18, chemokines, and
proteases, are subsequently produced. Further activation of the
M1 pathway occurs through the assembly of the NLR inflamma-
some and caspase-1 activation, which results in the conversion of
IL-1β and IL-18 into secreted active forms (62). With the NLRP3
inflammasome serving as a sensor of obesity-associated danger
signals, the progression of obesity can switch macrophages from
“M2-like”to“M1-like”cells (63). In macrophages, the activation of
NLR stimulates the cryptopyrin/NLRP3 inflammasome to induce
IL-1β and IL-18 production via caspase-1. Caspase-1 and IL-1β
are induced in adipose tissue with diet-induced obesity (DIO), and
Nlrp3- and caspase-1-deficient mice both demonstrate a resistance
to DIO-induced inflammation (63). The mechanism of this pro-
tective effect may be driven by the alteration of M1 activation of
ATMs, as Nlrp3-knockout mice show decreased M1 but increased
M2 gene expression in ATMs.
In addition to binding to TLRs, some pathogen-associated
molecular patterns (PAMPs) are also recognized by a family of
cytosolic nucleotide-binding receptors and NOD-like receptors
(NLRs) (64), another groups of PAMP receptors. Some NLRs
are involved in the recognition of microbial molecules and/or
endogenous factors released from tissue destruction. This recog-
nition can lead to activation of caspase-1 (a pro-inflammatory
caspase), and subsequent proteolytic conversion of potent pro-
inflammatory cytokines IL-1β and IL-18 from their precursors
pro-IL-1β and pro-IL-18, respectively. The proteolytic conversion
of IL-1β and IL-18 is mediated by a cytosolic caspase 1-activating
protein complex, termed as inflammasome (65).
As the most well-characterized members of the NLR fam-
ily, NOD1 is ubiquitously expressed and NOD2 is restricted to
monocytes, macrophages, dendritic cells, and intestinal Paneth
cells (66). Both NOD1 and NOD2 induce NF-κB activation in a
TLR-independent manner (67). Structural analysis demonstrated
that NOD1 and NOD2 recognize different core motifs derived
from peptidoglycan (PGN), a component of bacterial cell walls.
NOD1 activity is triggered byγ-d-glutamyl-meso-diaminopimelic
acid, a unique PGN structures from all Gram-negative and some
Gram-positive bacteria (68). In contrast, NOD2 is activated by
muramyl dipeptide, a PGN motif in all Gram-positive and Gram-
negative bacteria (69). Upon ligand recognition,NOD1 and NOD2
undergo conformational changes and self-oligomerization, which
is followed by the recruitment and activation of the serine threo-
nine kinase RICK (RIP2, also known as RIPK2), an essential step
for the activation of NF-κB and MAPKs. The ubiquitination of
RICK is essential for NOD1/NOD2-mediated signaling because
removal of this modification by deubiquitinating enzyme A20
largely dampens NOD1/NOD2-induced NF-κB activation (70,
71). Although both NOD1 and NOD2 induce similar K63-linked
ubiquitination of RICK for NF-κB activation and upregulation
of various inflammatory mediators, NOD2 signaling appears to
preferentially utilize the E3 ligase TRAF6 and NOD1-mediated
signaling is mainly associated with TRAF2 and TRAF5. Neverthe-
less, the role of NOD1 and NOD2 in activating NF-κB-dependent
inflammatory responses is not limited to the recognition of PGN
motifs. Recent study by Keestra et al. (72) reported that that NOD1
can sense activation state of small Rho GTPases. In this study,
NOD1 signaling pathway was triggered by RAC1 and CDC42
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activated by bacterial delivery or ectopic expression of SopE, a
virulence factor of the enteric pathogen Salmonella.
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING
FACTOR
As the most recently discovered cytokine involved in regulation
of macrophage polarization, granulocyte-macrophage colony-
stimulating factor (GM-CSF) is produced by a variety of cells
including macrophages and parenchyma cells. The main functions
of GM-CSF include regulating the proliferation and differenti-
ation of functional hematopoietic cells. The GM-CSF receptor
forms a dodecamer structure (73) and recruits JAK2, leading to the
activation of STAT5, extracellular signal-regulated kinase (ERK),
V-Akt murine thymoma viral oncogene homolog 1 (AKT), and the
nuclear translocation of NF-κB and IRF5 (21). Many of these regu-
lators are part of the IFN-γ and TLR signaling pathways. GM-CSF
enhances macrophage antigen presentation, complement- and
antibody-mediated phagocytosis, microbicidal capacity, leukocyte
chemotaxis, and adhesion. GM-CSF induces cytokine production
of IL-6, IL-8, G-CSF, M-CSF, TNF, and IL-1β in monocytes and
macrophages, although the degree of cytokine induction by GM-
CSF is less than that by LPS. Global gene expression analyses
of macrophages differentiated from GM-CSF-treated monocytes
showed that GM-CSF upregulated 340 genes and downregulated
190 genes in macrophages. Macrophage-specific genes including
CD14, CD163, C5R1, and FcγR1A, and several cell surface adhe-
sion molecules, cytokine receptors were induced by GM-CSF (74).
In this study, a high-resolution transcriptome profiling of human
macrophages by RNA sequencing was employed to discover novel
marker genes unique for human macrophages. A similar strategy
has been used to obtain a high-resolution transcriptome profile of
human macrophages under M1 (or M1-like) and M2 (or M2-like)
polarization conditions, resulting in a more comprehensive under-
standing of the transcriptome of human macrophages (75). The
GM-CSF deficient mice have normal numbers of macrophages
in many tissues but display an impaired maturation of alveolar
macrophages and develop pulmonary alveolar proteinosis (76). In
human beings, mutations in the GM-CSF receptor, especially in
the common beta chain, lead to alveolar macrophage dysfunction,
proteinosis, and malignancy (77, 78).
MicroRNAs
MicroRNAs (miRNAs), a class of 19–24 nt non-coding RNAs
that induce gene silencing at the posttranscriptional level,
have emerged as an important regulatory mechanism for gene
expression in many immune cells including monocytes and
macrophages (79, 80). Functional miRNAs associated with polar-
ized macrophages have been identified (81). While these functional
miRNAs like miR-155 and miR-146 are induced by a variety of
inflammatory stimuli, including LPS, TNFα, and IL-1β, they are
instrumental in attenuating TLR4/IL-1R signaling pathways in
monocytes and macrophages (79, 82, 83). These findings allow
us to postulate that miRNAs may contribute to the switching of
inflammatory macrophages to an immunosuppressive phenotype,
needed for resolution. For instance, miR-146, miR-125b, miR-155,
and miR-9 have been shown to be induced by LPS, and in turn,
these miRNAs inhibit TLR4/IL-1R signaling through regulation
of IRAK-1, TRAF6, IKKe, p50NF-jB, and TNFα at transcriptional
and posttranscriptional level (79, 82–86). Our recent study has also
shown that a panel of miRNAs including miR-17, miR-20a, and
miR-106a are stimulated by LPS through c-Myc pathway, and these
miRNAs collectively reduces the expression level of macrophage
differentiation related marker, signal-regulatory proteinα (SIRPα)
(87). It has been reported that miR-98 and miR-21 inhibit the
expression of inflammatory genes in monocytes and macrophages
via controlling IL-10 level (88, 89). These findings strongly argue
that miRNAs can regulate macrophage phenotype in the course of
various diseases, for example, during endotoxin tolerance (30, 90).
In the efforts to delineate the role of miRNAs in macrophage
activation in inflammatory diseases, Ponomarev et al. (91) found
that miR-124 promotes microglia quiescence and suppresses EAE
by deactivating macrophages in a C/EBPα-PU.1-dependent man-
ner. This is one of the few studies in which a specific miRNA
is found to regulate macrophage plasticity, although it remains
unclear how C/EBPα suppresses macrophage M2 polarization.
Zhang and co-workers (92) also reported that miR-223 modulates
obesity-associated adipose tissue inflammation through regulat-
ing macrophage activation. In the study, they found that miR-223
was upregulated in LPS-treated macrophages but downregulated
in IL-4-treated bone marrow-derived macrophages (BMDMs). In
agreement with the observation of differential expression of miR-
223 in various macrophages, the miR-223-deficient macrophages
were hypersensitive to LPS stimulation,whereas such macrophages
exhibited a delayed responses to IL-4 compared with controls.
Moreover, miR-223-deficient mice exhibited an increased adi-
pose tissue inflammatory response but a decreased adipose tissue
insulin signaling. They further identified Pknox1 as a genuine
target of miR-223. Although Pknox1 as a miR-223 target in regu-
lating macrophage polarization was validated by gain-of-function
and loss-of-function analyses in BMDMs, it remains unclear how
Pknox1 further regulates macrophage polarization.
A recent work by Banerjee et al. (93) demonstrated that
let-7c could regulate bactericidal and phagocytic activities
of macrophages, two functional phenotypes implicated in
macrophage polarization. In the study, they found that let-7c was
expressed at a higher level in M2-type macrophages than in M1-
type macrophages. When M2-type macrophages were re-polarized
to M1-type macrophages or M1-type macrophages converted to
M2-type macrophages, let-7c expression level was decreased or
increased, respectively. As LPS stimulation reduced let-7c expres-
sion in M2 macrophages, let-7c might play an inhibitory role
in modulating macrophage inflammatory responses. In line with
this, upregulation of let-7c in macrophages diminished M1 phe-
notype but promoted M2 phenotype polarization. Their study
further identified that let-7c targeted C/EBP-δ, a key transcrip-
tional factor in macrophage pro-inflammatory response to TLR4
stimulation (94, 95).
The modulation of macrophage polarization by miR-155 has
also been recently reported (96, 97). The expression of miR-155
was found to be repressed in naive macrophages or LPS-stimulated
Akt2-/- macrophages. In this process, miR-155 targets transcrip-
tional factor C/EBP-β, a hallmark of M2 macrophages. C/EBP-β
can regulate Arg1 and its level is increased upon Akt2 ablation.
Overexpression or depletion of miR-155 drove macrophages to
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M1 or M2 phenotype, respectively, confirming that miR-155 plays
a central role in regulating Akt-dependent M1/M2 polarization
of macrophages. It has also reported that miR-155 can directly
block IL-13-induced macrophage M2 phenotype via suppressing
the expression of IL-13Rα1 (96). As an oncomiR, miR-155 also tar-
gets SHIP1 to promote TNFα-dependent tumor cell growth (98).
Through overexpression of miR-155, we successfully re-polarized
tumor-associated macrophages (TAMs) into pro-inflammatory
M1 macrophages (97). Taken together, these studies support the
hypothesis that miR-155 is a key molecule in causing macrophage
polarization toward M1-type activity.
M1–M2 PHENOTYPE SWITCH
Macrophage differentiation is highly dynamic. Responding to
microenviromental cues macrophages can rapidly switch from
one phenotype to the other. In fact, activation of NF-κB or IRF
family members in macrophages by TLR4 or other TLRs can
drive macrophage to either M1 or M2 polarization under various
pathological conditions (99–105). Accumulating evidences have
shown that the spatiotemporal activation of NF-κB is a key reg-
ulator of the plasticity of macrophages observed in the courses
of various disease progressions. For example, during the early
phase of tumorigenesis, NF-κB activation in M1 macrophages
is critical for cancer-related inflammation. However, at the late
phase of tumorigenesis, macrophages are re-programed to TAM
or M2-like macrophages displaying low NF-κB activation but
increased immunosuppressive capacity (106). A similar situa-
tion of macrophage polarization is observed at different stages
along the progression of sepsis, in which NF-κB activation in
M1 macrophages drives the initial overt inflammatory phase,
while during the late phase of endotoxin tolerance, macrophages
are polarized to an anti-inflammatory, tumor growth-promoting
(M2) phenotype, and display an impaired NF-κB activation
(107). The studies on RSV infection also show that polariza-
tion of macrophages is complicated process and the phenotype
of macrophage activation can be varied at the different stage
along disease progression. As the most significant cause of lower
respiratory tract infection in infants and young children, RSV
infection is found to be associated with a mixed “Th1” and “Th2”
cytokine storm. At the initial stage of RSV infection, RAV induces
the expression of various anti-viral genes like IFN-β in airway
epithelial cells, and then promotes the expression of many NF-κB-
dependent pro-inflammatory genes in macrophages through stim-
ulating TLR4, TLR2, TLR3, and retinoic acid-induce gene I (RIG-
I), driving macrophages toward anti-viral, pro-inflammatory M1
phenotype. However, to maintain a mild but persisting infection,
RSV also induces alveolar macrophages to produce IL-4 and IL-
13 that contribute to macrophage M2 polarization and disease
resolution through IL-4Rα/STAT6-, TLR4-, and IFN-β-dependent
signaling pathways (45).
Although under certain conditions like parasite infections
and allergy, the functional phenotypes of macrophages in vivo
largely mirror those of canonical M1 and M2-polarized states,
macrophage populations often express mixed phenotypes in the
course of various disease settings. Indeed, macrophages with
combinations of M1 and M2 markers can be found in neurodegen-
erative disorders (108), atherosclerotic plaques (109), and some
murine tumors (110). Therefore, the contribution of coexisting
macrophages with different phenotypes, the impact of dynamic
changes of macrophage plasticity on diseases, and the molecular
networks orchestrating the switch of macrophage phenotype are
required to be analyzed for a full understanding of the M1–M2
paradigm of macrophage polarization.
FUTURE DIRECTIONS
Tremendous progress has been made in defining the mol-
ecular networks underlying M1–M2-polarized activation of
macrophages. Molecular determinants of M1–M2 polarization
include members of the PPAR, KLF, IRF, STAT, NF-κB, and HIF
families, and miRNAs. However, new molecules that regulate
macrophage M1–M2 polarization may still remain unidentified. A
novel class of large intergenic non-coding RNAs, termed as lincR-
NAs, has been recently shown to be involved in both activation and
repression of immune response genes (111). Among thousands of
lincRNAs identified in the mammalian genome, 159 lincRNAs was
found to be differentially expressed following innate activation of
THP1 macrophages (112). In these differentially expressed lin-
cRNAs, linc1992 was found to specifically bind to heterogenous
nuclear ribonucleoprotein L (hnRNPL) and form a linc1992-
hnRNPL complex that regulates TNFα gene transcription. The
role of lincRNAs in modulation of macrophage polarization, how-
ever, has not been reported so far but certainly needs to be further
studied.
Different from the irreversible phenotypic changes seen in
lymphocytes after exposure to polarizing cytokines, macrophage
polarization is transient and plastic. In order to adapt to
the microenvironmental conditions of surrounding tissues,
macrophages can rapidly switch their phenotypes. For example,
M2 macrophages can be re-polarized into macrophages with M1
phenotype following exposure to TLR ligands or IFNγ or overex-
pression of miR-155 (113, 114), whereas M1 macrophages can be
reprogramed to express various genes of M2 macrophage by treat-
ing macrophages with reagents that increase IL-10 level (115, 116).
Therefore, further exploring the dynamic process of macrophage
polarization and the mechanisms that govern this process not only
is important for our understanding of the M1–M2 paradigm of
macrophage polarization but also provides new therapeutic strate-
gies for various diseases including cancers via targeting imbalances
of macrophage polarization.
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